- Home
- EQR vs GMAB Comparison
EQR vs GMAB Comparison
Compare EQR & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQR | GMAB |
|---|---|---|
| Founded | 1993 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3B | 19.1B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | EQR | GMAB |
|---|---|---|
| Price | $60.01 | $26.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $69.54 | $40.93 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.60% | N/A |
| EPS Growth | ★ 8.09 | N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $2,701,075,000.00 | N/A |
| Revenue This Year | $4.33 | $17.80 |
| Revenue Next Year | $3.07 | $14.86 |
| P/E Ratio | $20.52 | ★ $1.90 |
| Revenue Growth | ★ 4.76 | N/A |
| 52 Week Low | $58.38 | $17.24 |
| 52 Week High | $72.65 | $35.43 |
Technical Indicators
Market Signals| Indicator | EQR | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 29.38 |
| Support Level | $59.04 | $20.83 |
| Resistance Level | $60.57 | $33.75 |
| Average True Range (ATR) | 1.26 | 0.64 |
| MACD | -0.44 | -0.13 |
| Stochastic Oscillator | 7.29 | 0.53 |
Price Performance
Historical ComparisonAbout EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.